Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Paragon 28, Inc. FNA NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score
36/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$13.00
-0.7%

Paragon 28, Inc. (FNA) is a Medical - Devices company in the Healthcare sector, currently trading at $13.09. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is FNA = $13 (-0.7% upside).

Financials: revenue is $256M, +20.2%/yr average growth. Net income is $55M (loss), growing at -124%/yr. Net profit margin is -21.3% (negative). Gross margin is 74.7% (-6.3 pp trend).

Balance sheet: total debt is $640,000 against $131M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 3.51 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $291M.

Analyst outlook: 3 / 7 analysts rate FNA as buy (43%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 55/100 (Partial), Future 26/100 (Fail), Income 10/100 (Fail).

$13.00
▼ 0.69% Downside
Average Price Target
The 12-month price target for Paragon 28, Inc. is $13.00.

FNA SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 35/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 55/100
Gross margin is + market cap
FUTURE 26/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — FNA

✗
VALUE Fail
35/100
FNA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $13, implying -0.7% from the current price $13. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
FNA: +20.2%/yr revenue is, -124%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet FNA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 3.51 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
55/100
FNA: Gross margin is 74.7% (-6.3 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 55/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
26/100
Analyst outlook: 3 / 7 analysts rate FNA as buy (43%). Analyst consensus target is $13 (-0.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
FNA: Net profit margin is -21.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.65-13.13
Volume16.57M
Avg Volume (30D)2.57M
Market Cap$1.1B
Beta (1Y)1.47
Share Statistics
EPS (TTM)-0.66
Shares Outstanding$83.31M
IPO Date2021-10-15
Employees525
CEOAlbert DaCosta
Financial Highlights & Ratios
Revenue (TTM)$256.18M
Gross Profit$191.49M
EBITDA$-23.4M
Net Income$-54.64M
Operating Income$-40.78M
Total Cash$34.58M
Total Debt$640K
Net Debt$-33.94M
Total Assets$290.72M
Price / Earnings (P/E)-19.8
Price / Sales (P/S)4.29
Analyst Forecast
1Y Price Target$13.00
Target High$13.00
Target Low$13.00
Upside-0.7%
Rating ConsensusHold
Analysts Covering7
Buy 43% Hold 57% Sell 0%
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS69913P1057

Price Chart

Track all markets on TradingView
FNA
Paragon 28, Inc. ↗  ·  NYSE
Healthcare • Medical - Devices
4.65 52WK RANGE 13.13

People Also View

GKOS
GKOS
Glaukos Corporation
$120.52
+0.86%
 BRKR
BRKR
Bruker Corporation
$39.90
+2.18%
 LIVN
LIVN
LivaNova PLC
$64.99
+0.63%
 ITGR
ITGR
Integer Holdings Corporation
$88.63
+1.03%
 NUVA
NUVA
NuVasive, Inc.
$39.75
-2.24%
 HSKA
HSKA
Heska Corporation
$119.99
+0.00%
 CNMD
CNMD
CONMED Corporation
$39.73
+3.30%
 IRMD
IRMD
IRadimed Corporation
$93.56
+0.02%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message